首页|重构本草——黄药子

重构本草——黄药子

扫码查看
通过古籍文献调研、中医药现代研究成果的梳理,结合中医临床及中药学等学科领域内知名专家学者认识及应用经验,归纳了黄药子功效主要为:化痰散结消瘿,清热解毒,凉血止血.标靶为甲状腺肿物,高甲状腺激素和低促甲状腺激素.现代药理研究发现黄药子及其有效成分具有补碘、调节甲状腺相关激素水平、抗肿瘤、抗炎等作用.具有肝肾毒性,黄独素B是主要的肝毒性成分.临床使用剂量为6~15 g,首次使用不超过15 g,使用时需配伍"保肝"中药,并在服药期间定期复查肝功能以及时减量或停药.总之,需根据不同疾病,或同一疾病的不同阶段进行辨证使用,并积极探索黄药子用量与标靶的量效关系构建.
Reconstruction of Chinese materia medica—air potato
Through the investigation of ancient literature and the sorting of modern research achievements in traditional Chinese medicine,combined with the understanding and application experience of well-known experts and scholars in the clinical and pharmaceutical fields of traditional Chinese medicine,it is concluded that air potato is mainly characterized by the follows:Its main effects include dissipating phlegm,resolving masses,eliminating goiters,clearing heat and detoxifying,cooling blood and stopping bleeding.Its biochemical indicator targets are thyroid neoplasms,high thyroid hormone and low thyroid-stimulating hormone.Modern pharmacological studies have found that its active ingredients have the functions of supplementing iodine,regulating thyroid related hormone levels,anti-tumor,anti-inflammation,etc.It has hepatotoxicity and nephrotoxicity,and the Diosbulbin B is the main hepatotoxicity component.Its clinical dosage range is 6-15 g,and should not exceed 15 g for the first time.When using it,it should be combined with"liver protecting"traditional Chinese medicine,and regularly check the liver function during the medication period,and reduce the dosage or stop it in a timely manner.In short,it is necessary to differentiate and use air potato according to different diseases or different stages of the same disease,and the dose-effect relationship between its dosage and biochemical indicator targets should be actively explored and reconstructed.

air potatobiochemical indicator targetsreconstruction of Chinese materia medicaclinical verification

胡诗宛、沈梦菲、林潼、周凌、金籽杉、张伟

展开 >

中国中医科学院广安门医院代谢病研究所,北京 100053

北京中医药大学,北京 100029

甘肃中医药大学基础医学院,兰州 730000

黄药子 标靶 重构本草 临床回归

北京中医药大学壶天客座教授科研启动经费资助项目

2023-XJ-KYQD-006

2024

吉林中医药
长春中医药大学

吉林中医药

CSTPCD
影响因子:0.843
ISSN:1003-5699
年,卷(期):2024.44(2)
  • 25